Cardiovascular Diseases Clinical Trial
Official title:
Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial
The aortic valve is located between the left ventricle and the aorta. Patients with
symptomatic, severe aortic valve stenosis conventionally have it surgically replaced
requiring direct access to the heart through the chest. Transcatheter aortic valve
replacement (TAVR) is now a well-established alternative for treating severe aortic valve
stenosis. Both types of intervention improve prognosis and alleviate symptoms.
The optimal choice of blood thinning therapy after TAVR is unknown. It has been reported that
leaflet thrombosis with reduced leaflet motion can occur and this phenomenon has been
suggested to be potentially related with neurological events. In addition, the occurence of
this phenomenon can be reduced with anticoagulation blood thinning therapy.
The purpose of this study is to evaluate if anticoagulation compared to the usual double
platelet inhibitor therapy after TAVR can reduce the risk of leaflet thrombosis.
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become an established
therapeutic option for patients with symptomatic, severe aortic valve stenosis, who are
ineligible or at high risk for conventional surgical aortic valve replacement (SAVR). It was
recently reported that leaflet thickening and reduced leaflet motion, verified by
four-dimensional computed tomography (4DCT), was not uncommon after both TAVR and SAVR. It
has been emphasized that this phenomenon should be further investigated for its effect on
clinical outcomes (e.g. stroke) and valve durability. As this valve leaflet thickening and
reduced motion could be reversed by oral anticoagulant (OAC) treatment and was not observed
in patients on chronic OAC therapy, it has been hypothesized that this phenomenon could be
related to possible leaflet thrombosis or a "thrombotic film" on the leaflets.
AIM: To evaluate whether a rivaroxaban-based strategy, following successful TAVR, compared to
an antiplatelet-based strategy, is superior in reducing subclinical valve leaflet thickening
and motion abnormalities - as detected by 4DCT-scan.
POPULATION: All patients undergoing successful TAVR by ileofemoral or subclavian access with
an approved TAVR device will be screened for eligibility. Included subjects must provide
written informed consent. Inclusion and exclusion criteria are listed below.
DESIGN: The GALILEO-4D trial will be conducted as a substudy of the multicenter, open-label,
randomized, event-driven, active-controlled GALILEO trial. Patients will be 1:1 randomized to
an antiplatelet-based strategy vs. rivaroxaban-based strategy - the randomization will adopt
the same 1:1 randomization of the main GALILEO trial. In case the GALILEO-4D trial should
still be continued after completion of the main GALILEO trial, this 1:1 randomization will be
continued until inclusion of 150 patients in both treatment groups. In total, 300 patients
will be randomized in the GALILEO-4D trial.
INTERVENTION: Subjects in the GALILEO-4D substudy will receive the same intervention as in
the main GALILEO study. In addition, a 4DCT-scan and echocardiography will be performed at 90
days after randomization.
END POINTS: The primary endpoint constitutes the rate of patients with at least one
prosthetic leaflet with > 50% motion reduction as assessed by cardiac 4DCT-scan (total N =
300). The secondary endpoints are listed below.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|